article thumbnail

EU pharma trade body starts genomic profiling initiative to improve access

Pharmaceutical Technology

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) and selected pharma and medical device companies have launched the European Coalition for Access to Comprehensive Genomic Profiling (ECGP), to promote the routine use of comprehensive genomic profiling.

Genome 264
article thumbnail

Modernizing cell culture processes for the next wave of genomic medicine

Pharmaceutical Technology

The field of genomic medicine has reached a true turning point. With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more.

Genomics 244
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innovation in immuno-oncology: Leading companies in gene therapy delivery using viral vectors

Pharmaceutical Technology

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Gene therapy delivery using viral vectors. Sanofi is one of the leading patent filers working with viral vectors.

article thumbnail

Ancient Genes of Zombie Viruses Revealed as Hidden Drivers of Cancer

AuroBlog - Aurous Healthcare Clinical Trials blog

Silently tucked away in our genomes, some of these bits of foreign DNA can get passed down through the generations. When viruses pay us a visit, they sometimes leave parts of themselves behind. They were long thought inactive, but we’ve since learned these stowaway sequences can be turned back on to wreak all sorts of […]

DNA 243
article thumbnail

Gene editing: beyond the hype

pharmaphorum

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Maybe in 50 years’ time we’ll be using gene editing to lower cholesterol, but it won’t replace statins in anyone but those with life threatening mutations for a long time”. Zinc fingers.

article thumbnail

Working for a mature form of genomic medicines

pharmaphorum

In a new episode of the pharmaphorum podcast, Rahul Kakkar, CEO of gene editing company Tome, speaks with web editor Nicole Raleigh about programmable genomic integration (PGI) technology.

Genome 118
article thumbnail

Hopewell Therapeutics raises funds for genomic medicines development

Pharmaceutical Technology

Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines. Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.

Genome 130